{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T16:40:36Z","timestamp":1792168836749,"version":"4.4.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To present a case series of eight patients with noninfectious chronic uveitis treated at a single institution with one of two JAK inhibitors (Jakinibs), upadacitinib or tofacitinib.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Subjects\/Methods<\/jats:title>\n                    <jats:p>A retrospective chart review of patients seen by the uveitis service from 2015 to 2022 treated with upadacitinib and\/or tofacitinib was performed. All patients included had previously failed alternative immunomodulatory therapy (IMT), had consistent ophthalmic evaluations for at least 6 months, and stayed on the Jakinib for at least 3 months. Eight patients were included. Demographic information was collected. Flares were classified clinically through visual acuity, symptoms, examination, and imaging. Side effects of the Jakinibs were recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median length of Jakinib therapy duration was 29.5 months (range 6 months\u201343 months). Five patients were initiated on a Jakinib due to poor control of their ocular inflammatory diseases. Four of these patients achieved control with tofacitinib with or without additional steroid use; one patient achieved control with upadacitinib with one mild flare that resolved with systemic steroid use. Three patients started a Jakinib due to poor systemic disease control. Two of those remained flare-free of uveitis in the following year. The third patient had a flare that resolved with topical and oral therapy. Gastrointestinal upset was the most common side effect of tofacitinib. Upadacitinib had no reported side effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Jakinibs may have a role in treatment of refractory noninfectious uveitis after failing conventional IMT. Both Jakinibs were well tolerated with a low incidence of side effects.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41433-025-04065-w","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T17:11:48Z","timestamp":1762449108000},"page":"91-97","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The use of Janus kinase inhibitors to treat noninfectious uveitis"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0283-8902","authenticated-orcid":false,"given":"Madeline","family":"Beckman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil K.","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Careen Y.","family":"Lowder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim","family":"Baynes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Lowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5769-0717","authenticated-orcid":false,"given":"Sumit","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"4065_CR1","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1056\/NEJMoa1509852","volume":"375","author":"GJ Jaffe","year":"2016","unstructured":"Jaffe GJ, Dick AD, Br\u00e9zin AP, Nguyen QD, Thorne JE, Kestelyn P, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375:932\u201343.","journal-title":"N Engl J Med"},{"key":"4065_CR2","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","volume":"388","author":"QD Nguyen","year":"2016","unstructured":"Nguyen QD, Merrill PT, Jaffe GJ, Dick AD, Kurup SK, Sheppard J, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388:1183\u201392.","journal-title":"Lancet"},{"key":"4065_CR3","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.ophtha.2017.11.017","volume":"125","author":"AD Dick","year":"2018","unstructured":"Dick AD, Rosenbaum JT, Al-Dhibi HA, Belfort R, Br\u00e9zin AP, Chee SP, et al. Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: fundamentals of care for uveitis (FOCUS) initiative. Ophthalmology. 2018;125:757\u201373.","journal-title":"Ophthalmology"},{"key":"4065_CR4","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1001\/jama.2019.12618","volume":"322","author":"SR Rathinam","year":"2019","unstructured":"Rathinam SR, Gonzales JA, Thundikandy R, Kanakath A, Murugan SB, Vedhanayaki R, et al. Effect of corticosteroid-sparing treatment with mycophenolate mofetil vs methotrexate on inflammation in patients with uveitis: a randomized clinical trial. JAMA. 2019;322:936\u201345.","journal-title":"JAMA"},{"key":"4065_CR5","doi-asserted-by":"crossref","unstructured":"Gangaputra SS, Newcomb CW, Joffe MM, Dreger K, Begum H, Artornsombudh P, et al. Comparison between methotrexate and mycophenolate mofetil monotherapy for the control of noninfectious ocular inflammatory diseases. Am J Ophthalmol. 2019;208:68\u201375.","DOI":"10.1016\/j.ajo.2019.07.008"},{"key":"4065_CR6","doi-asserted-by":"publisher","first-page":"1863","DOI":"10.1016\/j.ophtha.2014.04.023","volume":"121","author":"SR Rathinam","year":"2014","unstructured":"Rathinam SR, Babu M, Thundikandy R, Kanakath A, Nardone N, Esterberg E, et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology. 2014;121:1863\u201370.","journal-title":"Ophthalmology"},{"key":"4065_CR7","first-page":"67","volume":"8","author":"S Pasadhika","year":"2014","unstructured":"Pasadhika S, Rosenbaum JT. Biologics: targets and therapy Dovepress update on the use of systemic biologic agents in the treatment of noninfectious uveitis. Biol Targets Ther. 2014;8:67\u201381.","journal-title":"Biol Targets Ther"},{"key":"4065_CR8","first-page":"71","volume":"42","author":"A Franke","year":"2010","unstructured":"Franke A, McGovern PB, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn\u2019s disease susceptibility loci. Nat Publ Group. 2010;42:71.","journal-title":"Nat Publ Group"},{"key":"4065_CR9","doi-asserted-by":"crossref","unstructured":"Schwartz DM, Bonelli M, Gadina M, O'Shea JJ. Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nat Rev Rheumatol. 2016;12:25\u201336.","DOI":"10.1038\/nrrheum.2015.167"},{"key":"4065_CR10","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1167\/iovs.11-8440","volume":"53","author":"K Hu","year":"2012","unstructured":"Hu K, Hou S, Jiang Z, Kijlstra A, Yang P. JAK2 and STAT3 polymorphisms in a han chinese population with beh\u00e7et\u2019s disease. Invest Ophthalmol Vis Sci. 2012;53:538\u201341.","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"4065_CR11","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/j.ajhg.2012.02.020","volume":"90","author":"D Ellinghaus","year":"2012","unstructured":"Ellinghaus D, Ellinghaus E, Nair RP, Stuart PE, Esko T, Metspalu A, et al. Combined analysis of genome-wide association studies for Crohn's disease and psoriasis identifies seven shared susceptibility loci. Am J Hum Genet. 2012;90:636\u201347.","journal-title":"Am J Hum Genet"},{"key":"4065_CR12","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/NEJMoa073003","volume":"357","author":"EF Remmers","year":"2007","unstructured":"Remmers EF, Plenge RM, Lee AT, Graham RR, Hom G, Behrens TW, et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med. 2007;357:977\u201386.","journal-title":"N Engl J Med"},{"key":"4065_CR13","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ajoc.2018.12.001","volume":"13","author":"MA Paley","year":"2019","unstructured":"Paley MA, Karacal H, Rao PK, Margolis TP, Miner JJ. Tofacitinib for refractory uveitis and scleritis. Am J Ophthalmol Case Rep. 2019;13:53.","journal-title":"Am J Ophthalmol Case Rep"},{"key":"4065_CR14","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1080\/09273948.2019.1605453","volume":"27","author":"P Bauermann","year":"2019","unstructured":"Bauermann P, Heiligenhaus A, Heinz C. Effect of janus kinase inhibitor treatment on anterior uveitis and associated macular edema in an adult patient with juvenile idiopathic arthritis. Ocul Immunol Inflamm. 2019;27:1232\u20134.","journal-title":"Ocul Immunol Inflamm"},{"key":"4065_CR15","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1080\/09273948.2022.2069128","volume":"31","author":"K Baquet-Walscheid","year":"2023","unstructured":"Baquet-Walscheid K, Heinz C, Rath T, Scheel M, Heiligenhaus A. Beneficial effect of upadacitinib in an adult patient with juvenile idiopathic arthritis-associated uveitis after unsatisfactory response to tofacitinib: a case report. Ocul Immunol Inflamm. 2023;31:1079\u201380.","journal-title":"Ocul Immunol Inflamm"},{"key":"4065_CR16","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1055\/a-1766-6739","volume":"239","author":"J Schneider","year":"2022","unstructured":"Schneider J, Schalenbourg A, Dudler J, Guex-Crosier Y. Intermediate uveitis in an HLA-B27-positive patient treated with upadacitinib. Klin Monatsbl Augenheilkd. 2022;239:572\u20134.","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"4065_CR17","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.3389\/fmed.2021.764067","volume":"8","author":"Y Kaneko","year":"2022","unstructured":"Kaneko Y, Murakami T, Nishitsuka K, Takakubo Y, Takagi M, Yamashita H. Effectiveness of baricitinib in refractory seronegative rheumatoid arthritis and uveitis: a case report. Front Med. 2022;8:2994.","journal-title":"Front Med"},{"key":"4065_CR18","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1001\/jamaophthalmol.2024.2439","volume":"142","author":"SK Srivastava","year":"2024","unstructured":"Srivastava SK, Watkins TR, Nguyen QD, Sharma S, Scales DK, Dacey MS, et al. Filgotinib in active noninfectious uveitis: the HUMBOLDT randomized clinical trial. JAMA Ophthalmol. 2024;142:789\u201397.","journal-title":"JAMA Ophthalmol"},{"key":"4065_CR19","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","volume":"384","author":"T Bieber","year":"2021","unstructured":"Bieber T, Simpson EL, Silverberg JI, Tha\u00e7i D, Paul C, Pink AE, et al. Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med. 2021;384:1101\u201312.","journal-title":"N Engl J Med"},{"key":"4065_CR20","doi-asserted-by":"publisher","first-page":"100","DOI":"10.31138\/mjr.31.1.100","volume":"31","author":"CM Lin","year":"2020","unstructured":"Lin CM, Cooles FA, Isaacs JD. Basic mechanisms of JAK inhibition. Mediterr J Rheumatol. 2020;31:100\u20134.","journal-title":"Mediterr J Rheumatol"},{"key":"4065_CR21","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","volume":"77","author":"S Banerjee","year":"2017","unstructured":"Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM. JAK\u2013STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs. 2017;77:521.","journal-title":"Drugs"},{"key":"4065_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1476-9255-7-41","volume":"7","author":"DM Meyer","year":"2010","unstructured":"Meyer DM, Jesson MI, Li X, Elrick MM, Funckes-Shippy CL, Warner JD, et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1\/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm. 2010;7:1\u201312.","journal-title":"J Inflamm"},{"key":"4065_CR23","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1136\/annrheumdis-2017-211555","volume":"77","author":"KF Baker","year":"2018","unstructured":"Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn\u2019s disease and ulcerative colitis?. Ann Rheum Dis. 2018;77:175\u201387.","journal-title":"Ann Rheum Dis"},{"key":"4065_CR24","first-page":"431","volume":"27","author":"Y Furumoto","year":"2013","unstructured":"Furumoto Y, Gadina M. The arrival of JAK inhibitors: advancing the treatment of immune and hematologic disorders. BioDrugs Clin Immunother Biopharm Gene Ther. 2013;27:431 Oct.","journal-title":"BioDrugs Clin Immunother Biopharm Gene Ther"},{"key":"4065_CR25","doi-asserted-by":"crossref","unstructured":"Liu XB, Tang LS, Chen JW, Lin CS, Liu QH, Xu Q. Case report: a promising treatment strategy for noninfectious uveitis. Front Pharmacol. 2021:18;12.","DOI":"10.3389\/fphar.2021.784860"},{"key":"4065_CR26","first-page":"1","volume":"2014","author":"PB Meadow","year":"2014","unstructured":"Meadow PB, Nguyen J, Kesavarapu K. Tofacitinib citrate for ulcerative keratitis in a patient with rheumatoid arthritis. Case Rep Rheumatol. 2014;2014:1\u20133.","journal-title":"Case Rep Rheumatol"},{"key":"4065_CR27","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s10067-019-04875-w","volume":"39","author":"E Miserocchi","year":"2020","unstructured":"Miserocchi E, Giuffr\u00e8 C, Cornalba M, Pontikaki I, Cimaz R. JAK inhibitors in refractory juvenile idiopathic arthritis-associated uveitis. Clin Rheumatol. 2020;39:847\u201351.","journal-title":"Clin Rheumatol"},{"key":"4065_CR28","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1001\/jamaophthalmol.2018.3789","volume":"136","author":"S Sarny","year":"2018","unstructured":"Sarny S, Hucke M, El-Shabrawi Y. Treatment of mucous membrane pemphigoid with janus kinase inhibitor baricitinib. JAMA Ophthalmol. 2018;136:1420\u20132.","journal-title":"JAMA Ophthalmol"},{"key":"4065_CR29","unstructured":"Pfizer Inc. Pfizer Shares Co-Primary Endpoint Results from Post-Marketing Required Safety Study of XELJANZ\u00ae (tofacitinib) in Subjects with Rheumatoid Arthritis (RA) | Pfizer [Internet]. 2021 [cited 2022 Dec 9]. Available from: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-shares-co-primary-endpoint-results-post-marketing."},{"key":"4065_CR30","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386:316\u201326.","journal-title":"N Engl J Med"},{"key":"4065_CR31","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1136\/annrheumdis-2021-221915","volume":"81","author":"F Khosrow-Khavar","year":"2022","unstructured":"Khosrow-Khavar F, Kim SC, Lee H, Lee SB, Desai RJ. Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study. Ann Rheum Dis. 2022;81:798\u2013804.","journal-title":"Ann Rheum Dis"},{"key":"4065_CR32","unstructured":"EMA recommends measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders | European Medicines Agency. 2022 https:\/\/www.ema.europa.eu\/en\/news\/ema-recommends-measures-minimise-risk-serious-side-effects-janus-kinase-inhibitors-chronic."},{"key":"4065_CR33","unstructured":"FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions | FDA https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death."}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04065-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04065-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04065-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T17:03:27Z","timestamp":1767459807000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-025-04065-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["4065"],"URL":"https:\/\/doi.org\/10.1038\/s41433-025-04065-w","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"assertion":[{"value":"3 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SS reports consulting fees from 4DMT, Alimera, AbbVie, Apellis, Astellas, Bausch and Lomb, Clearside, Eyepoint, Harrow, Genetech\/Roche, Kodiak, Merck, Regeneron, RegenXBio, Ripple, Volk, and Zeiss, with contracted research support from Acelyrin, Gilead, Genetech\/Roche, Santen, IONIS, Kodiak. SKS reports grants from Regeneron, Eyevensys, Eyepoint, and Gilead, and consulting fees from Adverum, Novartis, Zeiss, and Bausch and Lomb.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}